Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Atezolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention. Browse Atezolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
512
Shown on this page
12
Current sort
Recently updated
Therapy scope
Atezolizumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Atezolizumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 301–312 of 512 matching trials for Atezolizumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 1Phase 2 Interventional Results available

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

NCT03024437
View directory record Official record
Conditions
Metastatic Cancer, Renal Cancer
Interventions
Atezolizumab, Bevacizumab, Entinostat
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Recruiting No phase listed Observational

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

NCT06717243
View directory record Official record
Conditions
Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
Interventions
Carboplatin/Cisplatin -Etoposide - Atezolizumab
Drug
Lead sponsor
Oncology Center of Biochemical Education And Research
Other
Eligibility
18 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

NCT04101357
View directory record Official record
Conditions
Solid Tumor, Extensive-stage Small Cell Lung Cancer
Interventions
BNT411, Atezolizumab, Carboplatin, Etoposide
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Terminated Phase 2 Interventional Results available

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

NCT04322643
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Avelumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

NCT02807636
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

NCT02724878
View directory record Official record
Conditions
Advanced Non-Clear Cell Kidney Cancer
Interventions
Bevacizumab, Atezolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Completed Phase 1 Interventional

ACTolog in Patients With Solid Cancers

NCT02876510
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
Fludarabine, Cyclophosphamide, IMA101 product, Recombinant human interleukin-2, IMADetect, Atezolizumab
Drug · Biological · Diagnostic Test
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

NCT04710498
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Atezolizumab
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Completed Phase 1 Interventional

Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

NCT05053737
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Atezolizumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Terminated Phase 2 Interventional Results available

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

NCT05776875
View directory record Official record
Conditions
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Interventions
Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
Drug · Combination Product
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

NCT04440735
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Interventions
DSP107, Atezolizumab
Biological
Lead sponsor
Kahr Medical
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 30, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NCT04632992
View directory record Official record
Conditions
Advanced Unresectable or Metastatic Solid Malignancy
Interventions
Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
38
States / cities
Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 30, 2026, 8:12 PM EDT

About this Atezolizumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Atezolizumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Atezolizumab.